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Introduction
Prostate cancer, the sixth most common cancer of all 
cancers, is the second most frequent malignancy in men 
around the world as well as the most common cancer in 
men in Europe, North America and parts of Africa [1, 2]. 
The number of new cases in 2000 amounted to 513,000 
people, in 2008 nearly 900,000 people (33 per 100,000 
population) and in 2012, about 1.1 million cases were 
estimated; it is expected that in 2030, the number of new 
cases of the disease will reach about 1.7 million people and 
the number of deaths is estimated to extend to 499,000 
people globally [3–5]. Recent international studies on the 
epidemiology of prostate cancer indicate a high incidence 
of this disease in Western countries [2, 6]. The highest 
incidences of this cancer are observed in Australia/New 
Zealand, North America, and northern and western parts 
of Europe [7–9]. On the other hand, over the past few dec-
ades, the incidence of prostate cancer in Asian countries 
has been much lower [7, 10, 11]. However, significant eco-
nomic growth as well as social and cultural adjustments in 
some Asian countries have led to an increase in life expec-
tancy, which has ultimately expanded the incidence and 
mortality of these cancers in these countries [12, 13]. The 
average mortality rate from this cancer in Asian countries 
was 3.8 per 100,000 [14]. The low incidence of prostate 
cancer in Asian countries can be due to various reasons, 
such as the lack of access to screening tests for diagno-
sis, other features including nutritional status, genetics, 
lifestyle, environmental factors, physical activity, smoking, 
race and registration cancer system [10, 15, 16]. Survival 
rates are one of the most important indicators for assess-
ing the quality of cancer control and treatment programs. 
According to studies, the survival rate of patients with 
cancer has increased in recent years [17]. Several studies 
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Survival Rate of Prostate Cancer in Asian Countries: 
A Systematic Review and Meta-Analysis
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Ali Hosseini¶, Hossein-Ali Nikbakht**, Mahdi Malakoutikhah††, Mohammad Taghi Ashoobi*, 
Mohammad Fathalipour‡‡, Hamid Salehiniya§ and Shirin Riahi§§
Background: Prostate cancer is one of the most common health issues among men, especially older men. 
In recent years, incidences of prostate cancer is increasing.
Objective: The aim of this study was to provide a comprehensive estimate of the survival of prostate 
cancer in Asian countries.
Methods: We searched five international databases including Medline/PubMed, Scopus, Embase, Web of 
Knowledge and ProQuest until June 1, 2018. The Newcastle-Ottawa Quality Assessment was used to eval-
uate the quality of selected papers. The review protocol was registered in PROSPERO (CRD42019117044).
Results: A total of 714 titles were retrieved. Thirty-seven studies met the inclusion criteria. Based on the 
random-effect model one-year, five-year and ten-year survival rate of prostate cancer were 81% (95% CI 
77.8–84.2), 61.9% (95% CI 59.5–64.3) and 36.2% (95% CI 9.2–63.2) respectively. Survival rates based on HDI 
level for five-year were 30.07, 43.43 and 70.84 percent for medium, high and very high levels, respectively.
Conclusion: According to the results of our study, the prostate cancer survival rate in Asian countries is 
relatively lower than in Europe and North America.
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which are conducted on the survival of this cancer in Asia 
have reported various results, as an illustration, see Chen 
et al. In the period of 1992 to 2000 in China, a five-year 
relative survival rate of prostate cancer estimated about 
32.5% [18]. However, Jung et al.’s study in South Korea for 
the two periods of 1996 and 2010–2014 revealed 67.2% 
and 93.3% survival rate respectively [18–21]. In a study in 
Iran, the overall five-year survival rate was 36.1% [22]. In 
another study conducted among different ethnic groups 
in China, the survival rate was reported to be 26.6% to 
78% over the years, which showed a noticeable fluctua-
tion trend and there was a significant difference between 
various ethnic groups [23]. In another study by Xu et al. 
in China, there was a significant difference between the 
five-year survival of prostate cancer patients with hyper-
tension (28.5%) and the control population (48.3%) [24].
Accurate information on the survival rate of pros-
tate cancer is essential, as it is used in various health 
and diagnostic planning [25, 26]. There is no compre-
hensive estimate of the survival rate of prostate can-
cer in Asian countries. Considering the importance of 
knowledge of the survival rate of this cancer in hospital 
planning and the different results between published 
articles, the purpose of this study was to provide a com-
prehensive estimate of the survival of prostate cancer 
patients in Asian countries through systematic review 
and meta-analysis.
Material and methods
The present study is a systematic review and meta-analysis 
study of prostate cancer survival in Asian countries. This 
study was designed and conducted in 2018. The meth-
odology of the present study is based on the PRISMA 
(Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses) statement [27]. The review protocol was 
registered in PROSPERO (CRD42019117044).
Search strategy
The researchers searched five international databases 
including Medline/PubMed, Scopus, Embase, Web of 
Knowledge, and ProQuest until June 1, 2018. We also 
searched the Google Scholar for detecting grey literature. 
Selected keywords for international databases included: 
(“Neoplasm”, “Cancer”, “Carcinoma”, “ Malignancy”, “ prostate 
Cancer”, “prostate Neoplasms”, “prostate  carcinoma”, 
“ prostate Tumor”, “Cancer of  prostate”, “ Neoplasms of 
prostate”, “Survival”, “Survival Analysis”, “Survival Rate”, 
“Afghanistan”, “Armenia”, “Azerbaijan”, “Bahrain”, 
“ Bangladesh”, “Bhutan”, “Brunei”, “Myanmar”,  “Cambodia”, 
“China”, “Georgia”, “Hong Kong”, “India”, “Indonesia”, “Iran”, 
“Iraq”, “Israel”, “Japan”, “Jordan”, “Kazakhstan”, “North Korea”, 
“South Korea”, “Kuwait”, “Kyrgyzstan”, “Laos”, “ Lebanon”, 
“Macau”, “Malaysia”, “Maldives”, “ Mongolia”, “Nepal”, 
“Oman”, “Pakistan”, “Philippines”, “Qatar”, “Saudi Arabia”, 
“Singapore”, “Sri Lanka”, “Syria”, “Taiwan”, “ Tajikistan”, 
“Thailand”, “Timor-Leste”, “Turkmenistan”, “United Arab 
 Emirates”, “Uzbekistan”, “Vietnam”, and “Yemen”).
The initial search was conducted by two researchers (SR 
and MF). The searched record entered the EndNote X7 
software, and duplicate articles were deleted.
Inclusion and exclusion criteria
All observational studies (cross-sectional, case-control, and 
cohort) stated the survival rate of localized prostate cancer 
in Asian countries were included in the study. Articles of 
other cancers reported survival in people who reported 
regional, metastatic, as well as review and meta-analysis 
studies were excluded. It should be noted that studies that 
did not report the sample size or confidence interval of 
survival rates were not included in the meta-analysis.
Quality assessment
The Newcastle-Ottawa Quality Assessment Form was 
used to evaluate the quality of selected papers. This tool 
has three different parts including selection (4 ques-
tions), comparability (1 question) and outcome (3 ques-
tions) and based on the final scores divided into three 
categories: good (3 or 4 stars in selection domain and 
1 or 2 stars in comparability domain and 2 or 3 stars in 
outcome/exposure domain), fair (2 stars in selection 
domain and 1 or 2 stars in comparability domain and 
2 or 3 stars in outcome/exposure domain) and poor (0 
or 1 star in selection domain or 0 stars in comparability 
domain or 0 or 1 stars in outcome/exposure domain) [28]. 
Results of quality assessment are presented in Appendix 1.
Screening of studies
Screening of studies, extraction of results, and evaluation 
of quality control of articles were performed separately 
independently by two authors (HD and EA). If there was 
no agreement between the two, the supervisor (SH) would 
announce the final comment on that article.
Data extraction form
All final articles entered into the study process were pro-
vided by a checklist that was previously prepared, and 
were arranged to extract the data. This checklist includes 
the name of the author, the year of publication, the period 
of the study, the country of origin, the survival rate by year 
for each survival period.
Statistical analysis
The heterogeneity of the studies was assessed by Cochran 
test (with significance less than 0.1) and its composition 
using I2 statistics. In the case of heterogeneity, the ran-
dom-effect model was utilized with the inverse-variance 
method, and in the absence of heterogeneity, the fixed-
effects model was applied. In the case of a heterogeneity 
in the studies, methods such as subgroup analysis were 
used and factors like the geographical area and the HDI 
considered in the analysis of subgroups. All analyzes were 
performed by the STATA (version 13) software.
Additional analysis
Due to the heterogeneity of the studies, the subgroups 
analysis was used. The indicator applied for this purpose 
is Human Development Index (HDI). The HDI is a relative 
measure of life expectancy, education, quality and educa-
tion level, and in general, it is the living standard in human 
societies. This index is estimated using the measure of 
welfare, especially among children and people of low age. 
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These statistics can be used to measure the development 
of countries, the impact of economic policies on living 
standards, and the survival of prostate cancer in each of 
the countries was reported to provide a clear indication 
of the prostate cancer survival status in each country [29].
Results
Study selection
After searching all the international databases, 714 arti-
cles were selected and after removing duplicate articles, 
the total was 556. After reviewing the titles and abstract 
of articles, 144 articles entered the next stage, at which 
point the full text was examined and 37 articles entered 
the final analysis. It should be noted that the referenced 
articles were also reviewed to add related studies. In the 
screening stages, some articles were excluded for a vari-
ety of reasons, which included unrelated topic (N = 289), 
unrelated population (N = 182), inadequate information 
(N = 44) and repeated results (N = 4). The study selection 
process is outlined in Figure 1.
Study characteristics
The included studies were published from 1998 to 2018. 
Based on geographical locations, nine studies were con-
ducted in Korea [19, 20, 21, 30, 31, 32, 33, 34, 35], five 
in China [18, 36, 37–39], five in Japan [40–44], four in 
India [45–48], four in Thailand [49–52], two in Singapore 
[53, 54], two in Taiwan [55, 56], one in Hong Kong [57], 
one in the Philippines [58], one involved Chinese resi-
dents in Singapore [59], one involved countries (China, 
India and Singapore) [60], one involved the Asian popula-
tion in England [61]. Characteristics of the included stud-
ies are presented in Table 1.
Quality appraisal
The results of the quality assessment of the articles have 
been shown in Appendix 2. Based on our results, 35 
studies have good and 2 studies have a fair quality.
Results of the meta-analysis
First, the articles were sorted according to the year of pub-
lication and then analyzed by the one-, five- and ten-year 
survival rate. It should be noted that the number of papers 
discussing two- and four-year survival rate was very low, 
and the results of the three-year survival rate were not 
very reasonable due to that most of the less-developed 
countries and lower HDI were reported.
One-year survival rate
Of the most recent papers, 23 number reported one-year 
survival rate. Based on the random-effect model, the 
results of the study demonstrated that one-year survival 
rate in Asian countries was 81% with a 95% confidence 
interval of 77.8 to 84.2. One-year survival rate of prostate 
Figure 1: Flowchart of the included eligible studies in systematic review.
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Table 1: Basic information of included studies.
Order Author (year) Location Time period Sample size Survival Rate
1 5 10
1 Esteban (1998) Philippines 1987 58 66.00 15.60 NR
2 Fan Jin (1998) China 1988–1991 373 62.50 29.60 NR
3 Martin (1998) Thailand 1983–1992 157 65.20 28.70 NR
4 Sato (2002) Japan 1962–1966 27 NR 36.30 NR
1967–1971 32 NR 19.4 NR
1972–1976 46 NR 37.6 NR
1977–1981 51 NR 31.3 NR
1982–1986 58 NR 24.2 NR
1987–1991 88 NR 73.4 NR
1992–1994 114 NR 84.5 NR
5 Tsukuma (2006) Japan 1993–1996 4348 88.6 50.2 NR
6 Jung (2007) Korea 1993–1997 NR NR 59.1 NR
1998–2002 NR 70.6 NR
7 Lim (2009) Singapore 1978–1982 NR NR NR 16.5
1983–1987 NR NR 30.1
1988–1992 NR NR 31.6
1993–1997 NR NR 41.6
1998–2002 NR NR 45.2
8 Chia (2010) Chinese 
Residents in 
Singapore
1973–1977 NR NR 51.3 NR
1978–1982 NR 47.7
1983–1987 NR 55.7
1988–1992 NR 76.5
1993–1997 NR 76.3
1998–2002 NR 76.1
9 Chen (2011) China 1992–2000 55 37.7 15.2 NR
1982–1991 NR 20.7 NR
10 Chia (2011) Singapore 1993–1997 752 82.4 44.6 NR
11 Jayalekshmi (2011) India 1991–1997 32 93.5 22.1 NR
12 Jung (2011) Korea 1993–1995 NR NR 55.9 NR
1996–2000 NR NR 67.2 NR
2001–2005 NR NR 79.5 NR
2004–2008 NR NR 86.2 NR
13 Law (2011) Hong Kong 1996–2001 3206 87.8 55.6 NR
14 Martin (2011) Thailand 1990–2000 171 80.7 53.1 NR
15 Matsuda (2011) Japan 1993–1996 4220 NR 66.8 NR
1997–1999 4508 NR 75.5 NR
1993–1996 NR NR 96.5 NR
1997–1999 NR NR 97.6 NR
16 Sankaranarayanan 
(2011)
China 1996–2001 NR NR 78.2 NR
China 1992–2000 NR NR 36.3 NR
China 1992–1995 NR NR 54.2 NR
(Contd.)
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Order Author (year) Location Time period Sample size Survival Rate
1 5 10
China 1991–1999 NR NR 68.4 NR
India 1991–1997 NR NR 32.6 NR
India 1992–1999 NR NR 42.3 NR
Singapore 1993–1997 NR NR 64.3 NR
17 Sriplung (2011) Thailand 1990–1999 144 80.8 32.1 NR
18 Sumitsawan (2011) Thailand 1993–1997 107 78.8 30.4 NR
19 Xiang (2011) China 1992–1995 639 68.8 36.9 NR
20 Xishan (2011) China 1991–1999 423 74.5 52.5 NR
1981–1990 NR NR 41.0 NR
21 Yeole (2011) India 1992–1999 1463 64.3 24.0 NR
22 Chang (2012) Taiwan 2002 5933 NR 77.1 NR
2002 1392 NR 66.7 NR
2002 1591 NR 69.3 NR
2002 2761 NR 58.9 NR
23 Jung (2012) Korea 1993–1995 NR NR 55.9 NR
1996–2000 NR NR 67.2 NR
2001–2005 NR NR 79.9 NR
2005–2009 NR NR 87.6 NR
24 Balasubramaniam 
(2013)
India 1999–2002 371 92.0 62.0 NR
25 Ito (2013) Japan 2000–2004 NR 81.0 87.0 NR
26 Jung (2013) Korea 1993–1995 NR NR 55.9 NR
1996–2000 NR NR 67.2 NR
2001–2005 NR NR 80.1 NR
2006–2010 NR NR 90.2 NR
27 Ito (2014) Japan 2002–2006 19519 NR 89.2 78.0
2001–2004 NR 94.2 79.6 NR
28 Jung (2014) Korea 2007–2011 NR NR 92.0 NR
29 Takiar (2014) India 2011 1495 64.9 23.9 NR
30 Jung (2015) Korea 2008–2012 92.3 NR
31 Maringe (2015) England 
(South Asians)
1986–1995 310 92.3 54.4 NR
England (Non-
South Asians)
1986–1995 35550 84.4 51.0 NR
England 
(South Asians)
1996–2004 1052 95.2 78.4 NR
England (Non-
South Asians)
1996–2004 72724 95.0 81.1 NR
32 Chang-Mo Oh 
(2016)
Korea 2008–2013 NR NR 92.5 NR
33 Jung (2017) Korea 2010–2014 NR NR 93.3 NR
34 Chen (2018) China 2002–2014 NR 69.05 18.80 9.40
2002–2014 NR NR 13.80 NR
2002–2014 NR NR 24.00 NR
(Contd.)
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cancer based on HDI has been shown in Figure 2. Accord-
ing to the results, the highest one-year survival rate in 
countries with a high HDI level was 91% (95% CI, 95–87) 
and the lowest was for countries with high HDI levels 
71.3% (95% CI, 77.3–65.3).
Five-year survival rate
The five-year survival rate was 61.9% with a 95% confidence 
interval of 59.5 to 64.3. The results of the five-year survival 
rate by the HDI has been illustrated in figure  Figure 3. 
Based on the findings of our study, the highest five-year 
survival rate for countries with a high HDI level was 70.8% 
(95% CI, 68.5–73.1) and the lowest among countries with 
a medium HDI level of 30% (95% CI, 17.5–42.5).
Ten-year survival rate
A total of 11 studies reported 10-year survival rate. Based 
on the results, the 10-year survival rate was 36.2% with 
95% confidence interval of 9.2 to 63.2. Ten-year survival 
rate of prostate cancer by HDI has been shown in Figure 4. 
Based on the results, the highest survival rates for coun-
tries with a high HDI level were 40.8% (95% CI, 14.5–67) 
and the lowest for countries with high HDI levels 9.4 (95% 
CI, 3–23.5). It should be noted that countries with medium 
HDI levels did not report the 10-year survival rate.
Survival rate of prostate cancer in each country
Overall, the results of the survival of prostate cancer in 
nine countries and three other areas has been showed in 
the Table 2. The highest survival rates of one, five, and 
ten-year were reported in Japan (93), Korea (84.9), and 
Japan (78), respectively, and the lowest survival rates for 
these years were observed in China (64.1), Philippines 
(15.6), and China (9.4), respectively.
Meta-regression
Results of meta-regression showed a significant association 
between publication year and five-year survival rate. Thus, 
Order Author (year) Location Time period Sample size Survival Rate
1 5 10
35 Chien (2018) Taiwan 2000–2010 NR NR 80.06 NR
2000–2010 NR NR 71.62 NR
2000–2010 NR NR 76.6 NR
36 Jung (2018) Korea 2011–2015 NR NR 94.1 NR
37 Zeng (2018) China 2003–2005 11690 NR 53·8 NR
2006–2008 NR 60·8 NR
2009–2011 NR 59·2 NR
2012–2015 NR 66·4 NR
NR: Not Reported.
Figure 2: Forest plot of one-year survival rate of prostate cancer in Asian countries.
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Figure 3: Forest plot of five-year survival rate of prostate cancer in Asian countries.
Figure 4: Forest plot of ten-year survival rate of prostate cancer in Asian countries.
year of study is a cause of variability in results of five-year 
survival rate (Reg Coef = 0.022, p < 0.001). This association 
for one-year survival rate not statistically significant (Reg 
Coef = –0.010, p = 0.084). According to results, an increas-
ing survival rate across the study period was observed.
Another factor for inconsistency in results is HDI. HDI is 
a cause of variability in results of one (Reg Coef = 0.022, 
p < 0.001) and five-year survival rate (Reg Coef = 2.73, 
p < 0.001). According to results, an increasing survival rate 
was observed with higher HDI in countries.
Also, we examined the sample size as other  explanatory 
factor to variability in our study and results showed 
 sample size was another reason for this inconsistency (Reg 
Coef = –2.94 e–6, p = 0.194 for one-year, Coef = –0.00001, 
p = 0.001 for five-year survival rate). Studies with larger 
sample size had a higher survival rate, but this finding not 
statistically significant for one-year survival rate. Results 
of meta-regression is shown in Figure 5.
Discussion
Prostate cancer is one of the most principal and arising 
health issues among elderly men, with a recent increase in 
its incidence [2]. Given that the importance of this cancer 
among men, especially in developing countries, as well as 
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the many differences in the incidence and survival of this 
cancer in the world, awareness of survival is an important 
issue [62].
In this study, the survival rate of prostate cancer has 
been reported in Asia for one-. five-, and ten-year survival 
rate. These values for the one-. five-, and ten-year survival 
rate are 81.0 (77.8–84.2), 61.9 (59.5–64.3) and 36.2 (9.2–
63.2) respectively.
One-year survival rates for countries with high HDI 
were lower than those with a medium HDI index. The 
reason for this difference is the low number of studies 
and those are the medium HDI often reported in India, 
while articles in the category of high HDI are mostly from 
China.
According to the results of this study, the highest sur-
vival rate has been reported in the Asians residence in 
England, followed by Japan in the second place. On the 
other hand, China has the lowest one-year survival rate. It 
seems that the higher HDI is directly related to the higher 
survival rate, as countries such as Japan and Singapore, 
which have a much higher HDI, have higher survival rates. 
But this is not true in India, because it has a higher sur-
vival rate, although it has a lower HDI than China. With 
regard to the three levels of the HDI, countries at the 
second level of this index have the lowest survival rates. 
However, given the low levels of countries at each level, 
especially in countries with a medium HDI, there can cer-
tainly not be any reason for this difference, and it seems 
to be due to variations in demographic characteristics [7]. 
Another potential reason can be observed in the short run 
of one-year, since studies have reveal that in longer peri-
ods of time, the survival rate is closer to real value [63].
This difference has not been seen in five-year survival 
rate and the aggregate survival rate for the three levels of 
HDI has a certain trend, so that countries with a medium 
HDI have the lowest survival rates and countries with a 
very high HDI have the highest aggregate survival rates. 
This higher survival rate could be better for reasons such 
as improving lifestyle, nutritional status, physical activity, 
and the use of health care [64].
According to the results of the Coleman et al. study, 
the five-year survival rate in 31 countries manifested that 
variations in the standardized survival of the age range 
are very wide between countries. This difference, even 
after adjusting for dissimilarities in mortality due to other 
causes, remains the highest in the United States, which 
was more inflated in Caucasians compared to African-
Americans (92.4% versus 85.8%). These variations are due 
to reasons such as differences in treatment care and the 
stages of the diagnosed disease [65, 66].
Figure 5: Result of meta-regression for one (left) and five-year (right) survival rate based on HDI, sample size and year 
of study.
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In another study by Steele et al., conducted in 2017, the 
results showed that the survival rates of one and five-year 
were significantly higher than the findings of the present 
study in the years 2002–2003 and 2004–2009. In the for-
mer study, the one-year survival rate for both periods was 
98.6 and 98.8, while in the present study, this rate was 
81%. The five-year survival rate was 96.7% and 96.9%, 
respectively, which was much higher than the results of 
the present study, which was 61.9% [67].
Critz et al. reported a 10-year survival rate of prostate 
cancer in their study in 2013 approximately 75% [68]. The 
results of this study, conducted in the United States, have 
revealed that survival rate is nearly twice as high as the 
results of the present study (75% versus 36.2%).
In general, and according to the results of this study, the 
survival rate of 1, 5 and 10 years for prostate cancer among 
Asian countries is lower than normal worldwide. Also, 
countries with higher HDI have higher survival values. 
These values are higher for Asian people outside of Asia.
In this study, we performed meta-regression for three 
variables including publication year, HDI level and sample 
size. The reason for the meta-regression for these three 
variables was access to data through the included studies. 
The meta-regression result shows a significant relation-
ship between published year of the studies with five-year 
survival rate, HDI with one- and five-year survival rate, and 
sample size with five-year survival rate. The reason for the 
increase in survival rate over time can be due to introduc-
ing new treatments and interventions. Higher HDI can 
also lead to better access to new treatments and interven-
tions, and this can increase survival rate of patient with 
prostate cancer.
Study Limitations
There are certain limitations in systematic review studies, 
most notably in the absence of access to some of the infor-
mation that attempts were made to contact the authors of 
the study to resolve the problem, which in several cases 
did not receive an adequate response. One of the main 
limitations of our study was the failure to report sample 
size and the inability to calculate the confidence interval 
for survival, which did not allow the study to include the 
meta-analysis stage. Other limitations included a survival 
report of less than one-year (6 and 9 months), which, 
given the low level of these, had no significant effect on 
our results. Ultimately, due to the lack of studies reporting 
10-year survival, the correct estimate of survival requires 
more robust studies.
Recommendations for future research
According to the results of this study, estimating the sur-
vival rate of prostate cancer requires more extensive stud-
ies at the level of other Asian countries, especially in the 
West and Central Asia, as most studies in this study were 
conducted in South and Southeast of Asia, and estimates 
are somewhat incorrect. Another suggestion could be a 
study of the survival of prostate cancer in patients who 
metastasized, which was not our study goal, and is an 
important issue in clinical decision making and the con-
tinuation of treatment.
Conclusion
According to the results of our study, the prostate cancer 
survival rate in Asian countries is relatively lower than 
in Europe and North America, which may be due to less 
access to diagnostic facilities and higher age at recogni-
tion of disease than to advanced countries. Another result 
of our study was the higher survival rate of prostate cancer 
in countries with very high HDI (such as South Korea and 
Japan), with similar survival rates as those of advanced 
countries such as Europe and North America.
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